
In summary, strategies for the metabolic and respiratory support of premature infants with HMD have been developed over the last 30 years. Most infants with a birth weight over 1000 g survive with supportive care. Surfactant treatments are an important addition that should decrease the need for respiratory support. Other problems of prematurity remain, although an improvement in respiratory care appears to simplify the care overall. Many practical aspects of the treatment of infants with surfactant must yet be evaluated. If surfactant therapy proves to be efficacious and safe, it may ultimately be a major advance in the care of premature infants with HMD.
Respiratory Distress Syndrome, Newborn, Hyaline Membrane Disease, Infant, Newborn, Humans, Pulmonary Surfactants, Lung, Respiration, Artificial
Respiratory Distress Syndrome, Newborn, Hyaline Membrane Disease, Infant, Newborn, Humans, Pulmonary Surfactants, Lung, Respiration, Artificial
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
